Senti Biosciences News

Senti Biosciences Announces Executive Team Reshuffle and New CFO

TipRanksMay 3 04:44

Senti Bio Announces Publication Of SENTI-202 Preclinical Data Demonstrating Potential Of Logic-Gated CAR-NK Cell Therapy For The Treatment Of Acute Myeloid Leukemia

Senti Bio Announces Publication Of SENTI-202 Preclinical Data Demonstrating Potential Of Logic-Gated CAR-NK Cell Therapy For The Treatment Of Acute Myeloid Leukemia

BenzingaApr 30 20:11

Senti Bio Announces Publication of SENTI-202 Preclinical Data; Says Data Supports The Design Of Phase 1 Clinical Trial With Patient Dosing Anticipated In Q2

Senti Bio Announces Publication of SENTI-202 Preclinical Data; Says Data Supports The Design Of Phase 1 Clinical Trial With Patient Dosing Anticipated In Q2

BenzingaApr 30 20:10

Senti Biosciences CFO Resigns, Transitions to Consultancy Role

TipRanksApr 27 05:15

Wolf Popper LLP Announces Investigations on Behalf of Investors in Materially Underperforming Special Purpose Acquisition Companies

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of investors in the following Special Purpose Acquisition Companies (SPAC). The stock prices of these companies,

GlobeNewswireApr 4 22:40

Senti Biosciences 4Q Rev $0.00 >SNTI

Senti Biosciences 4Q Rev $0.00 >SNTI

Dow JonesMar 22 04:13

Senti Biosciences Q4 2023 GAAP EPS $(0.42) Misses $(0.28) Estimate

Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.28) by 50 percent.

BenzingaMar 22 04:11

Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M

04:09 PM EDT, 03/21/2024 (MT Newswires) -- Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M

MT NewswiresMar 22 04:09

Press Release: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Dow JonesMar 22 04:05

Senti Biosciences Transfers Listing to Nasdaq Capital Market

TipRanksFeb 7 18:02

Senti Biosciences Said Reducing Its Workforce By ~37% As Part Of Prioritizing Its Investment In Lead Clinical Program

Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platf

BenzingaJan 6 05:07

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersKaruna Therapeutics (NASDAQ:KRTX) shares increased by 47.4% to $317.1 during Monday's pre-market session. The company's market cap stands at $11.9 billion. Universe Pharmaceuticals (NASDAQ:UPC)

BenzingaDec 25, 2023 21:05

Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?

Yahoo FinanceDec 23, 2023 01:12

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersKaruna Therapeutics (NASDAQ:KRTX) stock moved upwards by 47.9% to $318.17 during Friday's pre-market session. The company's market cap stands at $12.0 billion. Senti Biosciences (NASDAQ:SNTI) s

BenzingaDec 22, 2023 21:07

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells.

Senti BiosciencesDec 22, 2023 13:00

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersReshape Lifesciences (NASDAQ:RSLS) shares rose 58.2% to $0.4 during Tuesday's after-market session. The company's market cap stands at $5.2 million. NightHawk Biosciences (AMEX:NHWK) shares mov

BenzingaDec 13, 2023 05:31

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersExicure (NASDAQ:XCUR) stock rose 54.5% to $0.66 during Thursday's after-market session. The market value of their outstanding shares is at $5.7 million. Aligos Therapeutics (NASDAQ:ALGS) stock

BenzingaDec 8, 2023 05:31

Senti Biosciences GAAP EPS of -$0.83 Misses by $0.39, Revenue of $0.04M Misses by $0.66M

Seeking AlphaNov 14, 2023 15:32

Senti Biosciences Q3 2023 EPS $(0.34) Up From $(0.38) YoY, Revenue $338K

Senti Biosciences Q3 2023 EPS $(0.34) Up From $(0.38) YoY, Revenue $338K

BenzingaNov 14, 2023 06:42

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers180 Life Sciences (NASDAQ:ATNF) stock moved upwards by 15.8% to $0.54 during Monday's after-market session. This security traded at a volume of 1.4 million shares come close, making up 1011.8%

BenzingaNov 14, 2023 05:31